MCID: PLS007
MIFTS: 55

Plasmodium Falciparum Malaria malady

Categories: Infectious diseases

Aliases & Classifications for Plasmodium Falciparum Malaria

Aliases & Descriptions for Plasmodium Falciparum Malaria:

Name: Plasmodium Falciparum Malaria 12 14
Malaria, Falciparum 42 69
Falciparum Malaria 12 14
Plasmodium Falciparum Malaria, Unspecified 12
Falciparum Malaria [malignant Tertian] 12
Malaria Fever, Subtertian 12
Malignant Tertian Fever 12
Malaria Falciparum 52

Classifications:



External Ids:

Disease Ontology 12 DOID:14067
ICD10 33 B50 B50.9 B50.0
ICD9CM 35 084.0
MeSH 42 D016778
NCIt 47 C34798
UMLS 69 C0024535

Summaries for Plasmodium Falciparum Malaria

Disease Ontology : 12 A malaria described as a severe form of the disease caused by a parasite Plasmodium falciparum, which is marked by irrregular recurrence of paroxysms and prolonged or continuous fever.

MalaCards based summary : Plasmodium Falciparum Malaria, also known as malaria, falciparum, is related to hepatitis and malaria. An important gene associated with Plasmodium Falciparum Malaria is CR1 (Complement C3b/C4b Receptor 1 (Knops Blood Group)), and among its related pathways/superpathways are Innate Immune System and Allograft rejection. The drugs Amodiaquine and Artemether have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and neutrophil, and related phenotypes are hematopoietic system and cellular

Related Diseases for Plasmodium Falciparum Malaria

Diseases related to Plasmodium Falciparum Malaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 179)
id Related Disease Score Top Affiliating Genes
1 hepatitis 30.7 IFNG IL10 TNF
2 malaria 11.7
3 hemolytic anemia due to g6pd deficiency 11.2
4 pyridoxal 5'-phosphate-dependent epilepsy 10.4 IL10 TNF
5 tubular renal disease-cardiomyopathy syndrome 10.3 IL10 TNF
6 severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive 10.3 IFNG IL10 TNF
7 plantar wart 10.3 IFNG IL10 TNF
8 osteodysplasty precocious of danks mayne and kozlowski 10.3 IFNG IL10 TNF
9 parkinson disease 11 10.3 IFNG IL10 TNF
10 cyclosporiasis 10.3 IFNG IL10 TNF
11 ciliary discoordination, due to random ciliary orientation 10.3 CD36 IFNG IL10
12 senile reticular retinal degeneration 10.3 IFNG IL10 TNF
13 pancreatic signet ring cell adenocarcinoma 10.3 IFNG IL10 TNF
14 pulpitis 10.3 IFNG IL10 TNF
15 tularemia 10.3 IFNG IL10 TNF
16 ectodermal dysplasia bartalos type 10.3 IFNG IL10 TNF
17 asymptomatic neurosyphilis 10.3 IFNG IL10
18 hereditary alpha tryptasemia syndrome 10.3 IFNG IL10 TNF
19 rickettsialpox 10.3 IFNG IL10 TNF
20 chromoblastomycosis 10.3 CR1 ICAM1 TNF
21 abnormal retinal correspondence 10.3 IFNG IL10 TNF
22 plummer's disease 10.3 IFNG IL10 TNF
23 orbital osteomyelitis 10.3 IFNG IL10 TNF
24 disease of mental health 10.3 IFNG IL10 TNF
25 follicular adenoma 10.3 IFNG IL10 TNF
26 myiasis 10.3 IFNG IL10 TNF
27 heart conduction disease 10.3 IFNG IL10 TNF
28 motor peripheral neuropathy 10.3 IFNG IL10 TNF
29 lung combined large cell neuroendocrine carcinoma 10.3 CD55 HP IL10
30 hypotrichosis 4 10.3 ICAM1 IFNG TNF
31 glucose intolerance 10.3 IFNG IL18 TNF
32 burns 10.2 IFNG IL10 TNF
33 usher syndrome, type 2a 10.2 IFNG IL10 IL18
34 venezuelan hemorrhagic fever 10.2 ICAM1 IFNG TNF
35 red cell phospholipid defect with hemolysis 10.2 IFNG IL18 TNF
36 persistent mullerian duct syndrome 10.2 ICAM1 IL10 TNF
37 oral cavity cancer 10.2 ICAM1 IFNG TNF
38 pemphigus vulgaris 10.2 CD55 CR1 HP
39 heparane sulfamidase deficiency 10.2 HBB HP
40 dengue hemorrhagic fever 10.2 IFNG IL10 TNF
41 strawberry gallbladder 10.2 ICAM1 IFNG TNF
42 classic type lipoma 10.2 IFNG IL10 TNF
43 acquired polycythemia 10.2 ICAM1 IL10 TNF
44 anterior foramen magnum meningioma 10.2 IFNG IL10 TNF
45 liver inflammatory pseudotumor 10.2 IFNG IL10 TNF
46 blue toe syndrome 10.2 IFNG IL10 TNF
47 vulvar nodular hidradenoma 10.2 IFNG IL10 TNF
48 xanthogranulomatous cholecystitis 10.2 ICAM1 IL10 TNF
49 eye carcinoma in situ 10.2 IFNG IL18 TNF
50 amelogenesis imperfecta 10.2 ICAM1 IL10 TNF

Graphical network of the top 20 diseases related to Plasmodium Falciparum Malaria:



Diseases related to Plasmodium Falciparum Malaria

Symptoms & Phenotypes for Plasmodium Falciparum Malaria

MGI Mouse Phenotypes related to Plasmodium Falciparum Malaria:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.13 CD36 CD55 FCGR2A G6PD HP ICAM1
2 cellular MP:0005384 10.11 IL18 MB MIF CD36 G6PD HP
3 cardiovascular system MP:0005385 10.1 CD36 G6PD HP ICAM1 IFNG IL10
4 immune system MP:0005387 10 CD36 CHIT1 FCGR2A HP ICAM1 IFNG
5 mortality/aging MP:0010768 9.97 TNF CD36 DHFR DHPS FCGR2A G6PD
6 muscle MP:0005369 9.5 CD36 ICAM1 IFNG IL10 IL18 MB
7 neoplasm MP:0002006 9.1 HP ICAM1 IFNG IL10 MIF TNF

Drugs & Therapeutics for Plasmodium Falciparum Malaria

Drugs for Plasmodium Falciparum Malaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 245)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amodiaquine Approved Phase 4,Phase 3,Phase 2,Phase 1 86-42-0 2165
2
Artemether Approved Phase 4,Phase 3,Phase 2,Phase 1 71963-77-4 119380 68911
3
Artesunate Approved Phase 4,Phase 3,Phase 2,Phase 1 88495-63-0 6917864 5464098
4
Lumefantrine Approved Phase 4,Phase 3,Phase 2,Phase 1 82186-77-4 6437380
5
Mefloquine Approved Phase 4,Phase 2,Phase 3,Phase 1 53230-10-7 4046
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
7
Acetaminophen Approved Phase 4,Phase 3,Phase 1,Phase 2 103-90-2 1983
8
chloroquine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54-05-7 2719
9
Primaquine Approved Phase 4,Phase 3,Phase 2,Phase 1 90-34-6 4908
10
Pyrimethamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 58-14-0 4993
11
Sulfadoxine Approved Phase 4,Phase 3,Phase 2,Phase 1 2447-57-6 17134
12
Quinine Approved Phase 4,Phase 3,Phase 2 130-95-0 8549 3034034
13
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 1,Phase 2 723-46-6 5329
14
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 738-70-5 5578
15
Azithromycin Approved Phase 4,Phase 2,Phase 3,Phase 1 83905-01-5 55185 53477736 447043
16
Dapsone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 80-08-0 2955
17
Proguanil Approved Phase 4,Phase 2,Phase 3,Phase 1 500-92-5 4923
18
Nevirapine Approved Phase 4,Phase 1,Phase 2,Early Phase 1 129618-40-2 4463
19
Atovaquone Approved Phase 4,Phase 2,Phase 3,Phase 1 95233-18-4 74989
20
Morphine Approved, Investigational Phase 4 57-27-2 5288826
21
Permethrin Approved, Investigational Phase 4,Phase 3 52645-53-1 40326
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
23
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
24 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Antimalarials Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Artemether-lumefantrine combination Phase 4,Phase 3,Phase 2,Phase 1
29 Artemisinine Phase 4,Phase 3,Phase 2,Phase 1
30 Artemisinins Phase 4,Phase 3,Phase 2,Phase 1
31
Dihydroartemisinin Phase 4,Phase 3,Phase 2,Phase 1 71939-50-9 6918483
32
Lactitol Phase 4,Phase 3,Phase 1 585-86-4 3871
33
Piperaquine Phase 4,Phase 3,Phase 2,Phase 1 4085-31-8 5079497
34 Anthelmintics Phase 4,Phase 3,Phase 2,Phase 1
35 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Amodiaquine, artesunate drug combination Phase 4
37 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
38 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
39 Antipyretics Phase 4,Phase 3,Phase 1,Phase 2
40 Chloroquine diphosphate Phase 4,Phase 3,Phase 2,Phase 1 50-63-5
41 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
44 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Fanasil, pyrimethamine drug combination Phase 4,Phase 3,Phase 2,Phase 1
46 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
47 Renal Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
49 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Neuromuscular Agents Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 552)
id Name Status NCT ID Phase
1 Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria Unknown status NCT00902811 Phase 4
2 Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO Unknown status NCT01930331 Phase 4
3 Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics Unknown status NCT01944189 Phase 4
4 Assessment of Artesunate/Mefloquine in the Peruvian Amazon Unknown status NCT02084602 Phase 4
5 Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year Period Unknown status NCT01038063 Phase 4
6 Impact of Insecticide Resistance on Vector Control Unknown status NCT01713517 Phase 4
7 Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan Unknown status NCT01075945 Phase 4
8 Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate Unknown status NCT00238017 Phase 4
9 Introduction of Eurartesim® in Burkina Faso, Mozambique, Ghana and Tanzania Unknown status NCT02199951 Phase 4
10 Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A Unknown status NCT01704508 Phase 4
11 The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau Unknown status NCT00137566 Phase 4
12 Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand Unknown status NCT01662700 Phase 4
13 Evaluation of the Public Health Impact of Seasonal Intermittent Preventive Treatment (IPT) in Children in Senegal Unknown status NCT00712374 Phase 4
14 Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi Completed NCT00164359 Phase 4
15 In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria Completed NCT02637128 Phase 4
16 Artemisinin-based Combination Therapy for Treatment of Plasmodium Falciparum Malaria in North Sumatera, Indonesia Completed NCT02325180 Phase 4
17 Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan Completed NCT01019408 Phase 4
18 Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria Completed NCT00529867 Phase 4
19 Interactions Between Artemether-lumefantrine and Antiretrovirals in HIV-patients With Uncomplicated Malaria in Tanzania Completed NCT00885287 Phase 4
20 Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso Completed NCT01017770 Phase 4
21 Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria. Completed NCT02089841 Phase 4
22 Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger Completed NCT01755559 Phase 4
23 Efficacy of Amodiaquine-artesunate in Children Aged 6-59 Months With Uncomplicated P. Falciparum Malaria Completed NCT00425763 Phase 4
24 Cohort Study in Senegal Comparing Artesunate + Amiodaquine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Completed NCT00540410 Phase 4
25 Cohort Study in Uganda Comparing Artesunate + Amiodaquine (Coarsucam) Versus Artemether + Lumenfantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Completed NCT00699920 Phase 4
26 Tracking Resistance to Artemisinin (TRAC) Completed NCT01350856 Phase 4
27 Safety and Efficacy Study of Artesunate and Mefloquin in Children With Uncomplicated Malaria Completed NCT00978172 Phase 4
28 CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi Completed NCT00125489 Phase 4
29 Chloroquine and Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Guinea Bissau Completed NCT00426439 Phase 4
30 Assessing the Efficacy of Four Drug Combinations as the Next First-line Therapy for Uncomplicated Malaria in Malawi Completed NCT00164710 Phase 4
31 Chloroquine and Amodiaquine for Treatment of Malaria in Children Completed NCT00137514 Phase 4
32 Efficacy and Effectiveness of Combined Therapy for Uncomplicated Malaria Treatment in Peru Completed NCT00164216 Phase 4
33 The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children Completed NCT00137553 Phase 4
34 Examination of ACT Implementation in a Vivax / Falciparum Co-endemic Area Completed NCT00935688 Phase 4
35 Safety and Tolerability of Low Dose Primaquine Completed NCT02434952 Phase 4
36 Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers Completed NCT00301015 Phase 4
37 The ASAP Study - Therapeutic Efficacy of Atovaquone-proguanil vs. Artesunate-atovaquone-proguanil in Cambodia Completed NCT02297477 Phase 4
38 Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers Completed NCT00233337 Phase 4
39 A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects Completed NCT00859807 Phase 4
40 Kintampo Trial of Combination Therapy for Malaria Completed NCT00119145 Phase 4
41 Harmonized AS/MQ Efficacy Study - Thailand Completed NCT02052323 Phase 4
42 Plasmodium Falciparum Artemisinin Resistance Vietnam Completed NCT01775592 Phase 4
43 Efficacy and Cost Effectiveness of Malaria Diagnosis Procedures and the Rational Use of ACT in Zanzibar Completed NCT00549003 Phase 4
44 Amodiaquine+Artesunate for Uncomplicated Malaria Treatment Completed NCT01213433 Phase 4
45 Treatment of Malaria With Quinine Plus Sulfadoxine-Pyrimethamine Completed NCT00167739 Phase 4
46 Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function Completed NCT00444106 Phase 4
47 Parenteral Artesunate Compared to Quinine as a Cause of Late Anaemia in African Children With Malaria Completed NCT02092766 Phase 4
48 Amodiaquine-Artesunate & Artemether-Lumefantrine Efficacy in Burkina Faso Completed NCT01697787 Phase 4
49 Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During Pregnancy Completed NCT00495508 Phase 4
50 Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo Completed NCT02741024 Phase 4

Search NIH Clinical Center for Plasmodium Falciparum Malaria

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: malaria, falciparum

Genetic Tests for Plasmodium Falciparum Malaria

Anatomical Context for Plasmodium Falciparum Malaria

MalaCards organs/tissues related to Plasmodium Falciparum Malaria:

39
Testes, T Cells, Neutrophil, Monocytes, Endothelial, Brain, Hypothalamus

Publications for Plasmodium Falciparum Malaria

Articles related to Plasmodium Falciparum Malaria:

(show top 50) (show all 714)
id Title Authors Year
1
Congenital Plasmodium falciparum Malaria in Washington, DC. ( 28077745 )
2017
2
Association of CD40L gene polymorphism with severe Plasmodium falciparum malaria in Indian population. ( 28352049 )
2017
3
Expression of cleaved caspase-3 in renal tubular cells in Plasmodium falciparum malaria patients. ( 26729581 )
2017
4
Risk of drug resistance in Plasmodium falciparum malaria therapy-a systematic review and meta-analysis. ( 28028628 )
2017
5
High Rate of Treatment Failures in Nonimmune Travelers Treated With Artemether-Lumefantrine for Uncomplicated Plasmodium falciparum Malaria in Sweden: Retrospective Comparative Analysis of Effectiveness and Case Series. ( 27986683 )
2017
6
Plasmodium falciparum malaria co-infection with tick-borne relapsing fever in Dakar. ( 28077149 )
2017
7
Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in CA'te d'Ivoire. ( 28049523 )
2017
8
Age and geographic patterns of Plasmodium falciparum malaria infection in a representative sample of children living in Burkitt lymphoma-endemic areas of northern Uganda. ( 28320389 )
2017
9
Evidence of non-Plasmodium falciparum malaria infection in KAcdougou, SAcnAcgal. ( 28049489 )
2017
10
Multicenter Pivotal Clinical Trial of Urine Malaria Test for Rapid Diagnosis of Plasmodium falciparum Malaria. ( 27847373 )
2017
11
Placental Sequestration of Plasmodium falciparum Malaria Parasites Is Mediated by the Interaction Between VAR2CSA and Chondroitin Sulfate A on Syndecan-1. ( 27556547 )
2016
12
The Link between Plasmodium falciparum Malaria and Endemic Burkitt's Lymphoma-New Insight into a 50-Year-Old Enigma. ( 26794909 )
2016
13
Potential for reduction of burden and local elimination of malaria by reducing Plasmodium falciparum malaria transmission: a mathematical modelling study. ( 26809816 )
2016
14
Evidence of a Mild Mutator Phenotype in Cambodian Plasmodium falciparum Malaria Parasites. ( 27100094 )
2016
15
Plasmodium falciparum malaria in 1(st)-2(nd) century CE southern Italy. ( 27923126 )
2016
16
Quantitative, model-based estimates of variability in the generation and serial intervals of Plasmodium falciparum malaria. ( 27660051 )
2016
17
Effect of Plasmodium falciparum malaria parasites on haematological parameters in Ghanaian children. ( 27413299 )
2016
18
Anemia, Iron Supplementation and Susceptibility to Plasmodium falciparum Malaria. ( 27919755 )
2016
19
Spatial and space-time distribution of Plasmodium vivax and Plasmodium falciparum malaria in China, 2005-2014. ( 27993171 )
2016
20
Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction. ( 26917051 )
2016
21
A non-pharmaceutical form of Artemisia annua is not effective in preventing Plasmodium falciparum malaria. ( 27432906 )
2016
22
A common TLR1 polymorphism is associated with higher parasitaemia in a Southeast Asian population with Plasmodium falciparum malaria. ( 26738805 )
2016
23
Plasmodium falciparum malaria parasitaemia among indigenous Batwa and non-indigenous communities of Kanungu district, Uganda. ( 27146298 )
2016
24
Hemolysis after Oral Artemisinin Combination Therapy for Uncomplicated Plasmodium falciparum Malaria. ( 27434054 )
2016
25
Polymorphisms in Pfcrt and Pfmdr-1 genes after five years withdrawal of chloroquine for the treatment of Plasmodium falciparum malaria in West Bengal, India. ( 27448953 )
2016
26
The return of chloroquine-susceptible Plasmodium falciparum malaria in Zambia. ( 27919256 )
2016
27
Fetal Hemoglobin Modifies the Disease Manifestation of Severe Plasmodium Falciparum Malaria in Adult Patients with Sickle Cell Anemia. ( 27872735 )
2016
28
Correction: Imputation-Based Population Genetics Analysis of Plasmodium falciparum Malaria Parasites. ( 27579790 )
2016
29
No Reduction in Hemoglobin Level in Severe Plasmodium falciparum Malaria Treated with Artesunate in Central Sudan. ( 27370816 )
2016
30
Severe imported Plasmodium falciparum malaria in French paediatric intensive care units. ( 27439418 )
2016
31
Estimation of the in-vivo minimum inhibitory concentration of cipargamin in uncomplicated Plasmodium falciparum malaria. ( 27872070 )
2016
32
Plasmodium falciparum malaria importation from Africa to China and its mortality: an analysis of driving factors. ( 28000753 )
2016
33
Parenteral Artesunate for Severe Imported Plasmodium falciparum Malaria in Children. ( 27518753 )
2016
34
A comparison of compliance rates with anti-vectorial protective measures during travel to regions with dengue or chikungunya activity, and regions endemic for Plasmodium falciparum malaria. ( 27378367 )
2016
35
Erratum to: Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. ( 27993147 )
2016
36
Impact of placental Plasmodium falciparum malaria infection on the Cameroonian maternal and neonate's plasma levels of some cytokines known to regulate T cells differentiation and function. ( 27871325 )
2016
37
Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Plasmodium falciparum Malaria in Children Aged Less than 15 Years in Guinea-Bissau - An Open-Label Non-Inferiority Randomised Clinical Trial. ( 27649561 )
2016
38
Pharmacokinetic properties of intramuscular versus oral syrup paracetamol in Plasmodium falciparum malaria. ( 27118212 )
2016
39
Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. ( 26906747 )
2016
40
Relative Susceptibilities of ABO Blood Groups to Plasmodium falciparum Malaria in Ghana. ( 26981125 )
2016
41
Investigation and control of a Plasmodium falciparum malaria outbreak in Shan Special Region II of Myanmar along the China-Myanmar Border from June to December 2014. ( 27109419 )
2016
42
Open-label trial on efficacy of artemether/lumefantrine against the uncomplicated Plasmodium falciparum malaria in Metema district, Northwestern Ethiopia. ( 27601913 )
2016
43
TRALI Syndrome During the Treatment of a Plasmodium falciparum Malaria Case. ( 28091389 )
2016
44
K13 mutations and pfmdr1 copy number variation in Plasmodium falciparum malaria in Myanmar. ( 26911145 )
2016
45
Adding a single low-dose of primaquine (0.25A mg/kg) to artemether-lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single-blinded clinical trial. ( 27565897 )
2016
46
Rosette-Disrupting Effect of an Anti-Plasmodial Compound for the Potential Treatment of Plasmodium falciparum Malaria Complications. ( 27403804 )
2016
47
Cord blood IgG and the risk of severe Plasmodium falciparum malaria in the first year of life. ( 27890694 )
2016
48
Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial. ( 27430374 )
2016
49
Efficacy and safety of pyronaridine-artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in western Cambodia. ( 26926629 )
2016
50
Artemisinin-Based Combination Therapy Versus Quinine or Other Combinations for Treatment of Uncomplicated Plasmodium falciparum Malaria in the Second and Third Trimester of Pregnancy: A Systematic Review and Meta-Analysis. ( 26788543 )
2016

Variations for Plasmodium Falciparum Malaria

Expression for Plasmodium Falciparum Malaria

Search GEO for disease gene expression data for Plasmodium Falciparum Malaria.

Pathways for Plasmodium Falciparum Malaria

Pathways related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

(show all 33)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 CD36 CD55 CHIT1 CR1 FCGR2A HBB
2
Show member pathways
12.78 CD55 ICAM1 IFNG IL10 TNF
3
Show member pathways
12.27 DHFR HBB ICAM1 IFNG TNF
4
Show member pathways
12.16 CR1 FCGR2A IFNG IL10 TNF
5
Show member pathways
12.11 IFNG IL10 IL18 TNF
6 12.05 ICAM1 IFNG SELE TNF
7 12.05 CR1 FCGR2A IFNG IL10 IL18 TNF
8
Show member pathways
11.91 IFNG IL10 IL18 TNF
9 11.91 FCGR2A ICAM1 IFNG MIF TNF
10 11.87 CD36 FCGR2A IFNG IL10 TNF
11
Show member pathways
11.85 CD36 HBB HP
12 11.85 CD36 CD55 CR1 TNF
13 11.83 ICAM1 SELE TNF
14 11.82 CD36 ICAM1 IL10 IL18 TNF
15 11.81 IFNG IL10 TNF
16 11.8 ICAM1 IFNG IL18 TNF
17 11.74 ICAM1 IFNG SELE
18 11.73 IFNG IL10 IL18 TNF
19 11.69 IFNG IL10 TNF
20 11.56 FCGR2A ICAM1 IL10
21 11.54 CR1 IL18 TNF
22 11.48 HP ICAM1 TNF
23 11.48 CD36 CR1 FCGR2A ICAM1 IL10 TNF
24 11.47 IFNG IL18 TNF
25 11.45 ICAM1 IL10 IL18 TNF
26
Show member pathways
11.45 ICAM1 IFNG MIF SELE TNF
27
Show member pathways
11.39 IFNG IL10 TNF
28 11.27 IFNG IL18 TNF
29 11.24 IFNG IL10 TNF
30 11.14 ICAM1 IFNG IL18
31 11.04 HBB ICAM1 IFNG IL10 IL18 SELE
32 10.97 CD36 CR1 HBB ICAM1 IFNG IL10
33 10.86 CD36 ICAM1 TNF

GO Terms for Plasmodium Falciparum Malaria

Cellular components related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.73 CD36 ICAM1 IFNG TNF
2 secretory granule membrane GO:0030667 9.63 CD55 CR1 FCGR2A
3 cell surface GO:0009986 9.63 CD36 CD55 CR1 ICAM1 MIF TNF
4 tertiary granule lumen GO:1904724 9.5 CHIT1 HBB HP
5 endocytic vesicle lumen GO:0071682 9.48 HBB HP
6 extracellular space GO:0005615 9.36 CD36 CHIT1 HBB HP ICAM1 IFNG
7 membrane raft GO:0045121 9.35 CD36 CD55 ICAM1 SELE TNF
8 haptoglobin-hemoglobin complex GO:0031838 9.26 HBB HP
9 extracellular exosome GO:0070062 10.07 CD55 CR1 FCGR2A G6PD HBB HP
10 extracellular region GO:0005576 10.06 CD55 CHIT1 HBB HP IFNG IL10

Biological processes related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

(show all 31)
id Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.92 IL10 IL18 MIF SELE TNF
2 leukocyte migration GO:0050900 9.91 ICAM1 MIF SELE TNF
3 defense response to bacterium GO:0042742 9.91 HP IFNG IL10 TNF
4 immune response GO:0006955 9.88 CD36 CHIT1 IFNG IL10 IL18 TNF
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.87 CD36 ICAM1 MIF TNF
6 negative regulation of gene expression GO:0010629 9.84 CD36 IFNG MIF TNF
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.81 CD36 ICAM1 MIF
8 viral entry into host cell GO:0046718 9.8 CD55 CR1 ICAM1
9 response to hydrogen peroxide GO:0042542 9.75 HBB HP MB
10 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.65 IFNG TNF
11 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.65 CD36 IL18
12 cellular response to lipopolysaccharide GO:0071222 9.65 CD36 ICAM1 IFNG IL10 TNF
13 leukocyte tethering or rolling GO:0050901 9.64 SELE TNF
14 oxygen transport GO:0015671 9.64 HBB MB
15 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.63 IL10 TNF
16 positive regulation of chemokine biosynthetic process GO:0045080 9.62 IFNG TNF
17 positive regulation of cytokine secretion GO:0050715 9.61 IL10 MIF TNF
18 endothelial cell apoptotic process GO:0072577 9.6 IL10 TNF
19 positive regulation of MHC class II biosynthetic process GO:0045348 9.59 IFNG IL10
20 regulation of removal of superoxide radicals GO:2000121 9.58 CD36 DHFR
21 negative regulation of cytokine secretion involved in immune response GO:0002740 9.56 IL10 TNF
22 neutrophil degranulation GO:0043312 9.56 CD36 CD55 CHIT1 CR1 FCGR2A HBB
23 type 2 immune response GO:0042092 9.55 IL10 IL18
24 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.51 MIF TNF
25 receptor biosynthetic process GO:0032800 9.49 IL10 TNF
26 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.48 ICAM1 TNF
27 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.46 IFNG TNF
28 positive regulation of nitric oxide biosynthetic process GO:0045429 9.46 HBB ICAM1 IFNG TNF
29 positive regulation of vitamin D biosynthetic process GO:0060557 9.37 IFNG TNF
30 positive regulation of blood microparticle formation GO:2000334 9.32 CD36 TNF
31 negative regulation of growth of symbiont in host GO:0044130 8.92 CD36 IFNG IL10 TNF

Molecular functions related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.33 CD55 CR1 ICAM1
2 oxygen transporter activity GO:0005344 9.26 HBB MB
3 cytokine activity GO:0005125 9.02 IFNG IL10 IL18 MIF TNF
4 hemoglobin binding GO:0030492 8.96 HBB HP

Sources for Plasmodium Falciparum Malaria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....